The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1.
 
Yoichi Naito
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; FUJIFILM Toyama Chemistry; Gardant Pharmaceuticals; Hisamitsu Pharmaceutical; Lilly; MSD; Mundipharma; Novartis; Ono Yakuhin; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie; AstraZeneca Japan; Boehringer Ingelheim; Chugai/Roche; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
 
Yukinori Ozaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin International; Lilly; Pfizer
 
Hitoshi Tsuda
Honoraria - Daiichi Sankyo; Roche
Consulting or Advisory Role - Daiichi Sankyo; Roche Dianostics
Research Funding - Goryo Chemical
 
Keita Sasaki
No Relationships to Disclose
 
Keisuke Kanato
No Relationships to Disclose
 
Takashi Hojo
No Relationships to Disclose
 
Norikazu Masuda
Leadership - Japan Breast Cancer Research Group; Japan Society of Clinical Oncology (JSCO); Japanese Breast Cancer Society
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Gilead Sciences; Kyowa-Kirin; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono-Pharma (Inst); Pfizer (Inst); Sanofi (Inst)
 
Fumikata Hara
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
 
Tadahiko Shien
Consulting or Advisory Role - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Nihonkayaku (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)